Congress Presentations
Stay informed about the latest scientific and medical research from Axsome.
Neuroscience Education Institute (NEI) Congress
Colorado Springs, CO | November 09 - 12, 2023
AXS-05 | Major Depressive Disorder
Improvements in Cognitive and Physical Functioning Outcomes in Depressed Individuals Treated with AXS-05 (Dextromethorphan-Bupropion): Results from the EVOLVE Open-Label, Long-Term Study
AXS-05 | Major Depressive Disorder
AXS-05 (Dextromethorphan-Bupropion) Significantly Improved Functioning in Major Depressive Disorder: Analysis of the Domains of the Sheehan Disability Scale
AXS-05 | Major Depressive Disorder
Impact of AXS-05 (Dextromethorphan-Bupropion) on Patient-Reported Insomnia Symptoms: Results from the GEMINI Trial
AXS-05 | Major Depressive Disorder
Assessment of Withdrawal Symptoms After Discontinuation of AXS-05 (Dextromethorphan-Bupropion) Treatment: Results from the GEMINI Trial
Solriamfetol | Excessive Daytime Sleepiness
Solriamfetol Improves Cognitive Performance in Preclinical Models of Sleep Apnea and in a Randomized Placebo-Controlled Study of Sleep Apnea Participants (SHARP)
Solriamfetol | Excessive Daytime Sleepiness
Effects of Solriamfetol on Cognitive Function in Participants with Cognitive Impairment Associated with Excessive Daytime Sleepiness in Obstructive Sleep Apnea: Results of the SHARP Study
Solriamfetol | Excessive Daytime Sleepiness
SURWEY Study of Solriamfetol: Initiation, Titration, Safety, Efficacy, and Follow-Up Experience for Patients with OSA in Germany
Solriamfetol | Excessive Daytime Sleepiness
Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea: Effect Sizes and Numbers Needed to Treat or Harm
